Company intelligence / Profile preview

Repair Biotechnologies

Syracuse, New York, United Statesrepairbiotechnologies.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Repair Biotechnologies has demonstrated rapid and significant reversal of atherosclerosis and reduction in liver fibrosis in mouse models using its LNP-mRNA CDP therapy. The company received favorable preclinical feedback from the FDA for MASH and plans preclinical meetings for atherosclerosis and familial hypercholesterolemia. No human clinical results yet.

Therapeutic areas: Metabolic DisordersCardiovascular
Modalities: mRNA therapies (LNP-mRNA)Gene therapy
Industry: Biotech

Drug pipeline

2 assets

CDP therapy

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

no major pharma partnerships publicly disclosed; early partnership with ReNAgade mentioned but not detailed or confirmed as ongoing.

Beyond the preview

Go deeper on Repair Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Repair Biotechnologies.

Explore the full profile